| Detailed information |
|---|
| CancerLivER ID | 2189 |
| Biomarker | miR-101-3p, miR-106b-3p, miR-1246 |
| Biomarker Name/Symbol (given in Publication) | miR-101-3p + miR-106b-3p + miR-1246 |
| Biomolecule | miRNA |
| Subject | Human |
| Degree of Validity | Potential diagnostic marker for HCC and validated on independent dataset |
| Experimental Condition | HCC v/s Control |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCC |
| Level of significance | p < 0.001 |
| Source | Plasma |
| PMID | 29632649 |
| Type of Biomarker | Diagnostic |
| Pathway | cancer- associated processes |
| Cohort | 62 clinically diagnosed HCC patients, 41 patients with liver cirrhosis and 25 healthy controls (not affected by liver diseases or any neoplastic disorder); |
| Sensitivity | 100 |
| Specificity | 100 |
| Accuracy | 100 |
| AUC | 1 |
| Disease | Human HCC, Cirrhosis |
| Year of Publication | 2018 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |